Dimensional Fund Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Dimensional Fund Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.2K	Buy	29,332 +10,968	+60%	+$18.6K	﹤0.01%	3188
2026 Q1	$25.4K	Hold	18,364	–	–	﹤0.01%	3200
2025 Q4	$44.3K	Sell	18,364 -1,215	-6%	-$2.64K	﹤0.01%	3216
2025 Q3	$35.5K	Sell	19,579 -2,625	-12%	-$3.69K	﹤0.01%	3252
2025 Q2	$26.4K	Sell	22,204 -21,950	-50%	-$30.1K	﹤0.01%	3261
2025 Q1	$90K	Buy	44,154 +7,091	+19%	+$38.2K	﹤0.01%	3212
2024 Q4	$223K	Buy	37,063 +6,239	+20%	+$45.3K	﹤0.01%	3146
2024 Q3	$216K	Buy	30,824 +20,758	+206%	+$164K	﹤0.01%	3157
2024 Q2	$58.4K	Buy	+10,066	New	+$81.1K	﹤0.01%	3298

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors's ACRV Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Acrivon Therapeutics (ACRV) stake by 60% in Q2 2026, buying an estimated $18.6K and bringing the position to 29,332 shares worth $52.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3188.

Dimensional Fund Advisors first reported a position in ACRV in Q2 2024 and has held it in 9 quarters since. The position peaked at $223K in Q4 2024. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Dimensional Fund Advisors held 29,332 shares of Acrivon Therapeutics worth $52.2K as of Q2 2026.
Dimensional Fund Advisors bought 10,968 Acrivon Therapeutics shares in Q2 2026, an estimated $18.6K.
Acrivon Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #3188 holding.
Dimensional Fund Advisors first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 9 quarters since.
Dimensional Fund Advisors's Acrivon Therapeutics position peaked at $223K in Q4 2024.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.